imiglucerase

Trade name: cerezyme

Recombinant proteinapprovedOrphan Drug FDA

Approved

May 23, 1994

Imiglucerase is a medication used in the treatment of Gaucher's disease. — Wikipedia

Clinical trial activity

26 trials · 31 clinical orgs · 3 marketing orgs

Phase 1
4
Phase 2
14
Phase 3
12
Phase 4
8

Earliest trial started Dec 1, 1997 (NCT00365131)

Timeline

1990s

  1. Nov 5, 1991

    Orphan Drug Designation

  2. May 23, 1994

    Genzyme — Earliest FDA Approval

  3. May 23, 1994

    Genzyme — NDA Organization

2000s

  1. Jan 1, 2005

    Shire — Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2007

    Shire — Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2007

    Shire — Earliest Phase 3 Sponsor(trial)

2010s

  1. Feb 26, 2010

    Shire — NDA Secondary Org

  2. Feb 26, 2010

    Takeda — NDA Secondary Org

Indications

Mechanism of action

Approval history

  • approvedMay 23, 1994

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only
Multi-specific
No

Oral

No

Parenteral

Yes

Topical

No

Black box warning

Sources

Also known as

  • cerezyme
  • d-glucosyl-n-acylsphingosine glucohydrolase
  • ec 3.2.1.45
  • ec 3.2.1.45
  • ga-gcb
  • glucosylceramidase
  • isu302
  • velaglucerase alfa
  • velaglucerase alfa
  • velaglucerase alfa
  • velaglucerase alfa
  • velaglucerase alfa
  • velaglucerase alfa
  • velaglucerase alfa
  • velaglucerase alfa
  • velaglucerase-alfa
  • vpriv
  • vpriv
  • vpriv
  • vpriv

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05529992Phase 3Dec 12, 2022Takeda
NCT05222906Phase 3Apr 18, 2022Genzyme, Sanofi
NCT04718779Phase 4Apr 22, 2021Takeda
NCT04656600Phase 4Dec 31, 2020Sanofi
NCT04787887Phase 1Jan 29, 2020ISU Abxis Co., Ltd., Scientia Clinical Research Limited Sydney
NCT03702361Phase 4Sep 4, 2018Hebrew University
NCT03485677Phase 3Apr 11, 2018Sanofi
NCT02574286Phase 4May 1, 2016Shire
NCT04120506Phase 4Jan 10, 2016Hebrew University, Shire
NCT02528617Phase 4Jul 1, 2015Baylor University, Texas Scottish Rite Hospital for Children
NCT01842841Phase 3Mar 1, 2013IQVIA, Shire
NCT01951989Phase 2Nov 1, 2012University Clermont Auvergne
NCT01685216Phase 1/Phase 2 (Phase 2)Sep 1, 2012Shire
NCT01614574Phase 3Mar 1, 2012Shire
NCT02770625Phase 3Sep 1, 2011Cairo University, ISU Abxis Co., Ltd.
NCT01161914Phase 3Jan 1, 2011ISU Abxis Co., Ltd.
NCT01881633Phase 1Oct 1, 2010ISU Abxis Co., Ltd.
NCT00943111Phase 3Sep 1, 2009Genzyme
NCT00954460N/AAug 5, 2009Shire
NCT00635427Phase 3May 1, 2008Shire
Showing 20 of 26 trials
Page 1 / 2

Organizations

Research & Development (31)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
ShireFor profit111042005
Hebrew UniversityAcademic/Hospital6232005
GenzymeFor profit4421997
ISU Abxis Co., Ltd.For profit4422010
SanofiFor profit3222018
Baylor UniversityAcademic/Hospital2122007
La Rabta HospitalAcademic/Hospital2012007
Sociedad Espanola de Socorros MutuosAcademic/Hospital2012007
TakedaFor profit2222021
University of LondonAcademic/Hospital2012007
University of ZaragozaAcademic/Hospital2012007
All India Institute of Medical SciencesAcademic/Hospital1012008
Cairo UniversityAcademic/Hospital1012011
Children's Memorial Health Institute, PolandAcademic/Hospital1012007
Duke UniversityAcademic/Hospital1012008
Emory UniversityAcademic/Hospital1012007
IQVIAFor profit1012013
Malabar Institute of Medical SciencesAcademic/Hospital1012008
Maria Sklodowska Curie Children's HospitalAcademic/Hospital1012005
Mother and Child Health Care Institute of SerbiaAcademic/Hospital1012005
31 organizations
Page 1 / 2

Marketing (4)

OrganizationOrg typeRelationshipDate
GenzymeFor profitNDAMay 23, 1994
GenzymeFor profitIND
ShireFor profitNDA2Feb 26, 2010
TakedaFor profitNDA2Feb 26, 2010